International Stem Cell Corporation (ISCO)

OTCMKTS: ISCO · Delayed Price · USD
0.00 (0.00%)
Jul 18, 2024, 4:00 PM EDT - Market closed
Market Cap 577.12K
Revenue (ttm) 7.83M
Net Income (ttm) -311,000
Shares Out 8.00M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 200
Open 0.1000
Previous Close 0.0721
Day's Range n/a
52-Week Range 0.0500 - 0.1500
Beta 0.25
Analysts n/a
Price Target n/a
Earnings Date n/a

About ISCO

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson’s disease, as well as for treating stroke, traumatic brain injury, and Alzheimer’s disease. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Comple... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 29
Stock Exchange OTCMKTS
Ticker Symbol ISCO
Full Company Profile

Financial Performance

In 2023, ISCO's revenue was $7.79 million, a decrease of -4.78% compared to the previous year's $8.18 million. Losses were -$131,000, -71.89% less than in 2022.

Financial Statements


Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.

TOKYO--(BUSINESS WIRE)--Kasturba medical college, XVIII Fujio cup quiz winners along with finalists become FCQ elites, an eligibility to nominate Edogawa NICHE Prize awardees.

9 months ago - Business Wire

International Stem Cell Corporation Announces Strong Financial Results for the Quarter Ended March 31, 2022

SAN DIEGO, CA / ACCESSWIRE / May 17, 2022 / International Stem Cell Corporation (OTC PINK:ISCO) ( ("ISCO" or "the Company"), a California-based clinical stage biotechnolo...

2 years ago - Accesswire